Don't sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda's oral proteasome inhibitor (MLN9708) at this year's ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015. Ixazomib is
OncLive.com posted a six member panel discussion about the two experimental drugs most likely to be approved next by the FDA: elotuzumab and ixazomib (MLN9708). The impressive group of panelists included doctors James R. Berenson, Sundar Jagannath, Shaji Kumar, Sagar Lonial, Keith K. Stewart and Jeffrey A. Zonder. Here's a write-up about the exchange, along
Thank God pomalidomide is working for me! But what do we do once it's not? Dr. Roy and I had a chance to discuss that on Monday. First the good news. Dr. Roy's gut feeling is that POM should work well for quite some time. And statistics back him up. Patients that respond like I
There are a half dozen experimental anti-myeloma drugs nearing the end of the research pipeline. Which is most likely to be approved and when? A biologic immunotherapy drug like elotuzumab or daratumumab? Millennium's new oral proteasome inhibitor, MLN9708? Although it only works well when combined with another drug like Revlimid, elotuzumab is the farthest along.
It's time. Christmas is behind us in the rear view mirror. New Years is fast approaching. And most of us should be recovered from our ASH hangovers! Not literal hangovers from drinking Hurricanes at Pat O'Briens... No, I'm referencing the hangover from data overload left by over 800 myeloma related abstracts presented at this year's
March is Multiple Myeloma Awareness Month. Do we really need another? Read this and you tell me! As I greeted support group members arriving before last month's meeting, an older couple that I didn't recognize introduced themselves and headed inside. "We saw the announcement in the paper." The woman proudly announced loudly. "Are you the
Before shifting our focus to amyloidosis, I wanted to remind you that I have updated my December 28th post, in which I project how much longer a myeloma patient can expect to live once he or she has access to Kyprolis, pomalidomide and MLN9708. You may want to revisit that one. There was quite a
OK. Let's get real. Readers are asking, "How long will access to the new myeloma therapies featured at ASH help me live? Tricky question. Answering is like trying to hit a moving target. Complicating things are combination therapies. Even after a new myeloma drug is approved, experts still won't know how combining the new drug
Significant news on the immunotherapy front. A small bio-pharmaceutical company, Gliknik, put out a press release yesterday about their immunomodulator, post SCT study results that were presented at last week at ASH. Two things of note. First, this is another University of Pennsylvania hosted study. If you recall, Penn researchers administered the risky, yet highly
Much more from me about ASH later today. Check that. I have enough news and data to analyze and share for the next two weeks! In the meantime it sounds like some medical reporters are impressed with Millennium's MLN9708 study results here at ASH. Take a look: New Oral Drug in Multiple Myeloma May Be
Enough about me! Here's an excerpt I saved from earlier this week on OncLive.com, featuring an interview with Dana-Farber's Dr. Ken Anderson: Overcoming Genetic Transformation in Multiple Myeloma Bonnie Gillis - OriginallyPublished Online: Tuesday, November 6, 2012 The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, Kenneth C.
In case you missed it, the U.S. Food and Drug Administration has set a date for an advisory committee meeting to review the company’s application for approval of pomalidomide: November 8th of this year. The agency is expected to make a decision about pomalidomide’s (New trade name, Actimid) application sometime early in February, 2013. Pomalidomide
The Multiple Myeloma Research Consortium (MMRC) sent me a press release, touting the fact that, "The MMRC has opened more than 40 Phase I and Phase II clinical trials of both novel compounds and combination approaches that are thought to be active against high-priority targets." Impressive! The group has backed studies involving elotuzumab, Millennium's oral
Yesterday I passed-along the new name that was selected for Millennium's experimental proteasome inhibitor, MLN9708: ixazomib Is "ixazomib" a good choice? Who knows? But I will suggest a name that isn't very good: multiple myeloma. Isn't very good? IT STINKS! I'm an educated guy. A former business owner and teacher, I have a Masters degree--yet
Remember this name: ixazomib (ix az' oh mib) Originally dubbed MLN9708, Millennium Pharmaceutical's experimental proteasome inhibitor has as much potential to help patients as any new anti-myeloma drug in the research pipeline. So don’t you think that it deserved a name? To clarify, this isn’t the new drug’s trade name. Think about Onyx’s new proteasome
Here is information about Millennium's new, oral proteasome inhibitor, MLN9708. Looks like they are making good progress... Presentations at ASH Highlight results of Studies with MLN9708, First Oral Proteasome Inhibitorin Early Stage Clinical Trials in Multiple Myeloma CAMBRIDGE, Mass., Dec 13, 2011 Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited